Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:16:38 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:SYRE - SPYRE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SYRE - Q0.111.78·19.540.116.29-0.60-3.6333.25,2144,82717.11  17.185  16.0840.26  10.9117:22:37Jun 1715 min RT 2¢

Recent Trades - Last 10 of 4827
Time ETExPriceChangeVolume
17:22:37Q16.54-0.354
17:22:37Q17.100.2136
17:19:07Q17.100.2110
16:33:06Q16.29-0.601,547
16:08:32Q16.26-0.631
16:04:15Q16.29-0.601
16:04:11Q16.29-0.601
16:04:10Q16.29-0.601
16:04:03Q16.29-0.601
16:02:35Q16.29-0.6090

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-17 07:30U:SYRENews ReleaseSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
2025-06-16 16:05U:SYRENews ReleaseSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
2025-06-06 16:05U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2025-05-28 08:30U:SYRENews ReleaseSpyre Therapeutics to Participate in Upcoming June Investor Conferences
2025-05-08 16:05U:SYRENews ReleaseSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-05 08:00U:SYRENews ReleaseSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
2025-05-02 16:05U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2025-04-04 16:05U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2025-03-27 16:05U:SYRENews ReleaseSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
2025-03-07 16:40U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2025-02-27 16:05U:SYRENews ReleaseSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025-02-25 08:00U:SYRENews ReleaseSpyre Therapeutics to Participate in Upcoming March Investor Conferences
2025-02-19 08:00U:SYRENews ReleaseSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
2025-02-07 17:13U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2025-01-13 08:00U:SYRENews ReleaseSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
2025-01-03 17:20U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-12-18 08:00U:SYRENews ReleaseSpyre Therapeutics Added to the Nasdaq Biotechnology Index
2024-12-02 17:03U:SYRENews ReleaseSpyre Therapeutics Announces Grants of Inducement Awards
2024-12-02 08:00U:SYRENews ReleaseSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
2024-11-25 17:11U:SYRENews ReleaseSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference